AnnJI possesses a well-established drug discovery and development platform developed by Prof. Ji-Wang Chern at National Taiwan University with a capability to efficiently identify novel chemical entities (NCEs) for therapeutic indications with unmet medical need. In this platform, newly synthesized compounds are subject to activity-driven optimization and quickly enter non-clinical pilot testing including toxicity, pharmacodynamics, and pharmacokinetics studies. This platform allows medicinal chemists, biologist, and pharmacokinetic experts efficiently collaborate to identify and develop druggable molecules. The drug candidates are then selected and enter IND-enabling stage.
We look forward to further discussions with you.
Please fill out the form, and we will get right back to you.